الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
prialt
esteve pharmaceuticals gmbh - zícónótíð - injections, spinal; pain - verkjalyf - zícónótíð er ætlað til meðferðar við alvarlegum langvarandi sársauka hjá sjúklingum sem þarfnast verkjastillingar.
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 50 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 50 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 25 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 25 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
risperidone teva gmbh stungulyfsstofn og leysir, forðadreifa 37,5 mg
teva gmbh - risperidonum inn - stungulyfsstofn og leysir, forðadreifa - 37,5 mg
الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
jorveza
dr. falk pharma gmbh - budesonide - Öndunarfærasjúkdómar - antidiarrheals, þarma bólgueyðandi / antiinfective lyfjum - jorveza er ætlað til meðferðar við eosinophilic esophagitis (eoe) hjá fullorðnum (eldri en 18 ára).
الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
hyftor
plusultra pharma gmbh - sirolimus - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.
الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
clopidogrel tad
tad pharma gmbh - clopidogrel (as hydrochloride) - peripheral vascular diseases; stroke; myocardial infarction - blóðþurrðandi lyf - clopidogrel is indicated in adults for the prevention of atherothrombotic events in: , patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.
الاتحاد الأوروبي -
الأيسلاندية -
EMA (European Medicines Agency)
removab
neovii biotech gmbh - catumaxomab - ascites; cancer - Önnur æxlishemjandi lyf - removab er ætlað til að meðhöndla illkynja öndunarfærasjúkdóma hjá sjúklingum með epcam jákvæða krabbamein þar sem hefðbundin meðferð er ekki tiltæk eða ekki lengur unnt.
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
clindamycin eql pharma hart hylki 150 mg
eql pharma ab - clindamycinum hýdróklóríð - hart hylki - 150 mg
أيسلندا -
الأيسلاندية -
LYFJASTOFNUN (Icelandic Medicines Agency)
clindamycin eql pharma hart hylki 300 mg
eql pharma ab - clindamycinum hýdróklóríð - hart hylki - 300 mg